BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.

Trial Details

NCT ID
NCT07002216
Phase
PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Hodgkin Lymphoma Lymphoma
Interventions
  • Brentuximab Vedotin
  • Etoposide
  • Cyclophosphamide
  • Doxorubicin
  • Dacarbazine
  • Dexamethasone
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Men and women ≥18 years of age and ≤60 years of age on the day of signing the informed consent form (or the legal age of consent in the jurisdictio…
  • Patients must have histologic confirmation of classical Hodgkin Lymphoma (cHL) defined by the World Health Organization (WHO) classification.
  • Baseline Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Computed Tomography (CT) must demonstrate Fluorodeoxyglucose (FDG) avid lesion…
  • Patients must have a clinical stage consistent with:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hodgkin Lymphoma Lymphoma Trials on Trialify →